Keystone Lab Announces Addition of Tianeptine to Testing Menu
Tianeptine is an atypical tricyclic antidepressant often used for addressing anxiety and irritable bowel disease. It is not approved for any use by the United States Federal Drug Administration (FDA). Tianeptine is often described as "gas-station dope" and products containing tianeptine commonly use the street names of "ZaZa" or "Tianna". The FDA recently warned consumers to avoid purchasing or using any Neptune's Fix products, which is illegally sold with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.
In addition to tianeptine and its metabolite, tianeptine metabolite MC5, Keystone has also added clozapine, N-desmethylclozapine, aripiprazole, aripiprazole metabolite OPC-3373, modafinil, diphenhydramine, loperamide, and 7OH-mitragynine to its in-house menu.
"The ease of obtaining products with tianeptine, combined with effects of harm, overdosing, and death has been a major obstacle for many of our addiction clinic and recovery center clients throughout
If testing for tianeptine is a priority for your business, please contact Keystone Lab at 800-230-2991, or contact us directly on our website.
About Keystone Lab:
Keystone Lab is a dual CAP-accredited and CLIA certified lab providing clinical and forensic toxicology testing services for more than 35 years. Keystone has developed an innovative platform of services to ensure the success and growth of organizations throughout
Media Contact
David Price
Sales & Marketing Manager
[email protected]
828-771-3107
View original content to download multimedia:https://www.prnewswire.com/news-releases/keystone-lab-announces-addition-of-tianeptine-to-testing-menu-302060518.html
SOURCE Keystone Lab
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Euclid Marine Strengthens Cargo and Stock Throughput Team with Appointment of Kathleen Creedon as Senior Vice President
- Danaos Corporation Reports Second Quarter and Half Year Results for the Period Ended June 30, 2026
- PIMCO Closed-End Funds Declare Monthly Common Share Distributions
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share